What is BioLineRx?
BioLineRx is a pre-commercial biopharmaceutical entity headquartered in Israel with a strategic operational presence in the United States. The company functions as a bridge between early-stage scientific innovation and late-stage clinical commercialization. Its core business model centers on the acquisition and development of novel therapeutic candidates, which are then advanced through rigorous clinical trials. By focusing on high-unmet-need indications, BioLineRx has positioned itself as a pivotal player in the global healthcare sector, specifically within the oncology and rare disease markets. The company's integrated approach combines internal research expertise with external partnerships to optimize the development lifecycle of its investigational treatments.
How much funding has BioLineRx raised?
BioLineRx has raised a total of $125M across 4 funding rounds:
Stock Offering
$50M
Debt
$40M
Other Financing Round
$15M
Debt
$20M
Stock Issuance/Offering (2007): $50M, investors not publicly disclosed
Debt (2022): $40M led by Kreos Capital Group
Other Financing Round (2023): $15M, investors not publicly disclosed
Debt (2024): $20M featuring Kreos Capital Group and BlackRock
Key Investors in BioLineRx
Kreos Capital Group
Kreos Capital Group Ltd is a company that specializes in finance. It provides investment services and business management. The company was formed in 1998 and is headquartered in London, United Kingdom.
BlackRock
BlackRock is a global investment management firm headquartered in New York City with operations across North America, Europe, Asia, and other regions. Founded in 1988, the company offers a comprehensive range of investment products and services including mutual funds, exchange-traded funds (ETFs), and alternative investments.
What's next for BioLineRx?
Looking ahead, the strategic deployment of the $20M investment will likely focus on the maturation of the company's clinical pipeline and the strengthening of its commercial infrastructure. With a clear emphasis on oncology and rare disease therapeutics, BioLineRx is expected to prioritize the progression of its lead candidates through critical regulatory milestones. The firm's ability to secure debt-based financing from sophisticated institutional investors suggests a high level of confidence in its long-term clinical prospects and operational stability. Moving forward, stakeholders will be monitoring the company's progress in translating its current research into market-ready therapies, a move that will be essential for achieving long-term value creation and sustainable growth in the global biopharmaceutical market.
See full BioLineRx company page
